Mutation Analysis of Pancreatic Juice and Plasma for the Detection of Pancreatic Cancer.
DNA
KRAS
SMAD4
TP53
biomarkers
cell-free DNA (cfDNA)
circulating tumor DNA (ctDNA)
detection
diagnosis
liquid biopsy
mutation
pancreatic cancer
pancreatic juice
plasma
precision medicine
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Aug 2023
23 Aug 2023
Historique:
received:
13
06
2023
revised:
31
07
2023
accepted:
02
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Molecular profiling may enable earlier detection of pancreatic cancer (PC) in high-risk individuals undergoing surveillance and allow for personalization of treatment. We hypothesized that the detection rate of DNA mutations is higher in pancreatic juice (PJ) than in plasma due to its closer contact with the pancreatic ductal system, from which pancreatic cancer cells originate, and higher overall cell-free DNA (cfDNA) concentrations. In this study, we included patients with pathology-proven PC or intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia (HGD) from two prospective clinical trials (KRASPanc and PACYFIC) for whom both PJ and plasma were available. We performed next-generation sequencing on PJ, plasma, and tissue samples and described the presence (and concordance) of mutations in these biomaterials. This study included 26 patients (25 PC and 1 IPMN with HGD), of which 7 were women (27%), with a median age of 71 years (IQR 12) and a median BMI of 23 kg/m
Identifiants
pubmed: 37685923
pii: ijms241713116
doi: 10.3390/ijms241713116
pmc: PMC10487634
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Biocompatible Materials
0
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Am J Gastroenterol. 2020 Dec;115(12):2103-2108
pubmed: 33105193
Mol Oncol. 2017 Mar;11(3):295-304
pubmed: 28164427
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Gut. 2018 Dec;67(12):2081-2084
pubmed: 28988195
Cancer Cytopathol. 2022 Sep;130(9):726-734
pubmed: 35511415
Int J Mol Sci. 2020 Oct 28;21(21):
pubmed: 33126568
J Natl Cancer Inst. 2021 Sep 4;113(9):1246-1257
pubmed: 33555293
Gut. 2022 Jun;71(6):1152-1160
pubmed: 33820756
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Gastroenterol Hepatol. 2022 Oct;45(8):637-644
pubmed: 35092761
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Curr Opin Hematol. 2019 Jul;26(4):235-240
pubmed: 31045645
BMC Cancer. 2015 Oct 24;15:797
pubmed: 26498594
Sci Rep. 2015 Dec 16;5:18425
pubmed: 26669280
Cancer Invest. 2015 Mar;33(3):78-85
pubmed: 25647443
Cell Death Differ. 2021 May;28(5):1477-1492
pubmed: 33257846
Am J Epidemiol. 2013 Jun 15;177(12):1317-25
pubmed: 23729685
Clin Lab. 2016 Oct 1;62(10):1947-1953
pubmed: 28164530
J Oncol. 2021 May 26;2021:5569783
pubmed: 34135960
Gastrointest Endosc. 2022 Nov;96(5):801-813.e2
pubmed: 35537661
Transl Cancer Res. 2022 Nov;11(11):4137-4147
pubmed: 36523306
Ther Adv Med Oncol. 2021 Aug 18;13:17588359211033704
pubmed: 34422118
Pancreatology. 2022 Nov;22(7):973-986
pubmed: 35864067
BMC Cancer. 2019 Jan 5;19(1):11
pubmed: 30611220